SCHEMBL292192

SCHEMBL292192

CC1C(BC2=CC3CC(C2C)C3(C)C)=CC2CC1C2(C)C

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2840915 0.73 ALDH1A1 (0.32) ALDH1A1
SCHEMBL788339 0.73 ALDH1A1 (0.35) ALDH1A1
SCHEMBL3956646 0.73 ALDH1A1 (0.35) ALDH1A1
SCHEMBL868850 0.73 ALDH1A1 (0.35) ALDH1A1
SCHEMBL775459 0.73 ALDH1A1 (0.35) ALDH1A1
SCHEMBL774380 0.73 ALDH1A1 (0.35) ALDH1A1
SCHEMBL2844350 0.72 ALDH1A1 (0.31) ALDH1A1
SCHEMBL8712083 0.72 ALDH1A1 (0.31) ALDH1A1
SCHEMBL5934323 0.69
SCHEMBL4083837 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220396591-A1 METHOD FOR PREPARING ALKENYL AMINOBORANES AND THEIR DERIVATIVES, AND USES THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-12-15 US claimed
EP-4038075-A1 METHOD FOR PREPARING ALKENYL AMINOBORANES AND THEIR DERIVATIVES, AND USES THEREOF UNIVERSITE DE BORDEAUX (FR) 2022-08-10 EP claimed
WO-2021064205-A1 METHOD FOR PREPARING ALKENYL AMINOBORANES AND THEIR DERIVATIVES, AND USES THEREOF Universite de Bordeaux (FR) 2021-04-08 WO claimed
EP-2495235-B1 Process for the synthesis of prostaglandins and intermediates thereof NEWCHEM S P A (IT) 2015-08-05 EP claimed
WO-2014203278-A2 NOVEL PROCESS FOR THE PREPARATION OF (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-HEXAHYDRO-2-HYDROXY-1-[(3S)-3-HYDROXYOCTYL]-1H-BENZ[f]INDEN-5-YL]OXY]ACETIC ACID MSN LABORATORIES PRIVATE LIMITED (IN) 2014-12-24 WO claimed
WO-2009157019-A2 PROCESS FOR PREPARING EZETIMIBE USING NOVEL ALLYL INTERMEDIATES IND-SWIFT LABORATORIES LIMITED (IN) 2009-12-30 WO claimed
US-20090143611-A1 Hexafluoroalcohol-based Monomers and Processes of Preparation Thereof ST-JEAN PHOTOCHIMIE INC. (CA) 2009-06-04 US claimed
EP-2004639-A2 PROCESSES FOR THE SYNTHESIS OF AZETIDINONE Teva Pharmaceutical Industries Ltd (IL) 2008-12-24 EP claimed
US-20080032964-A1 Process for the synthesis of azetidinone TEVA PHARMACEUTICALS USA, INC. 2008-02-07 US claimed
WO-2007120824-A2 PROCESSES FOR THE SYNTHESIS OF AZETIDINONE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-10-25 WO claimed
WO-2006050609-A1 NEW HEXAFLUOROALCOHOL-BASED MONOMERS AND PROCESSES OF PREPARATION THEREOF ST-JEAN PHOTOCHIMIE INC. (CA) 2006-05-18 WO claimed
EP-0641304-B1 STEREO-SELECTIVE SYNTHESIS OF 2-ARYL-PROPIONIC ACIDS OF HIGH OPTICAL PURITY BY USING CHIRAL OXAZOLINES CHEMISCH BIOTECHNOLOGISCHE LAB (DE) 1998-04-08 EP claimed
EP-0641304-A1 STEREO-SELECTIVE SYNTHESIS OF 2-ARYL-PROPIONIC ACIDS OF HIGH OPTICAL PURITY BY USING CHIRAL OXAZOLINES CHEMISCH BIOTECHNOLOGISCHE LABORATORIEN GMBH (DE) 1995-03-08 EP claimed
EP-0641304-A4 STEREO-SELECTIVE SYNTHESIS OF 2-ARYL-PROPIONIC ACIDS OF HIGH OPTICAL PURITY BY USING CHIRAL OXAZOLINES. KUNICHEM INC (US) 1994-12-13 EP claimed
WO-1993013046-A1 STEREO-SELECTIVE SYNTHESIS OF 2-ARYL-PROPIONIC ACIDS OF HIGH OPTICAL PURITY BY USING CHIRAL OXAZOLINES KUNICHEM, INC. (US) 1993-07-08 WO claimed
EP-0188235-B1 PRODUCTION OF OPTICALLY PURE ORGANOBORANES Aldrich Chemical Company, Inc. (US) 1991-12-11 EP claimed
JP-8041074-A None JP disclosed
JP-4352745-A None JP disclosed
US-4594456-A Racemic and optically active 3-hydroxy-alpha-cyclocitral, its acetals and optically active 3-oxo-alpha-cyclocitral acetals, and their preparation BASF AKTIENGESELLSCHAFT (DE) 1986-06-10 US disclosed
US-4423255-A AND PYRETHROID ESTERS FMC CORPORATION (US) 1983-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032964-A1 Process for the synthesis of azetidinone CYP46A1, APOB, CYP51A1 ALDH1A1 464/4885
US-20220396591-A1 METHOD FOR PREPARING ALKENYL AMINOBORANES AND THEIR DERIVATIVES, AND USES THEREOF CTBP2, HBG2, BCL9L ALDH1A1 4475/4885
US-20090143611-A1 Hexafluoroalcohol-based Monomers and Processes of Preparation Thereof C1S, AFF1, AFF2 ALDH1A1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.